Therapeutics News

Ocuphire Pharma has enrolled the first patient in its LYNX-2 phase 3 registration study of phentolamine ophthalmic solution 0.75% for treatment of reduced visual acuity under low-light conditions after keratorefractive surgery.

Okyo Pharma has announced additional findings from its phase 2 trial of OK-101, including statistically significant improvement in ocular pain relief, conjunctival staining and tear breakup time in patients with dry eye disease.

NEW YORK — Optometrists may be the first to recognize adverse effects of systemic medications, which warrants collaboration with the prescribing physician, Jessica Steen, OD, FAAO, Dipl ABO, said at Vision Expo East.

Brassica Pharma has initiated a voluntary recall of its eye ointment products after an FDA inspection of a Brassica facility found a “lack of sterility assurance.”

ATLANTA — A long-term study of Vevye for treating dry eye showed an improvement in Schirmer’s scores by 98% at week 46, according to Walter O. Whitley, OD, MBA, FAAO.

Skye Bioscience has completed enrollment for its phase 2a trial of SBI-100, a cannabinoid receptor type 1 agonist being developed for patients with primary open-angle glaucoma or ocular hypertension, according to a company press release.

Biotechnology company Ocugen announced that dosing is complete in the first cohort of its phase 1/2 GARDian clinical trial of OCU410ST, a modifier gene therapy candidate for treatment of Stargardt disease.

Harrow has announced an exclusive out-licensing agreement with Apotex, a major Canadian pharmaceutical company, to market and distribute five of the company’s branded ophthalmic products.

Oculis has completed the first patient visit in its phase 3 OPTIMIZE-2 trial of OCS-01, the company’s preservative-free, once-daily topical formulation of dexamethasone for treating pain and inflammation after cataract surgery.

Skye Bioscience has treated the first patient in its phase 2 study of SBI-100 ophthalmic emulsion, a CB1 agonist delivered as an eye drop to treat patients with elevated IOP, according to a company press release.